Dexmedetomidine pharmacokinetics in pediatric intensive care - a pooled analysis

被引:131
|
作者
Potts, Amanda L. [1 ]
Anderson, Brian J. [1 ]
Warman, Guy R. [1 ]
Lerman, Jerrold [2 ,3 ]
Diaz, Susan M. [4 ,5 ]
Vilo, Sanna [6 ]
机构
[1] Univ Auckland, Dept Anaesthesiol, Auckland 1, New Zealand
[2] SUNY Buffalo, Women & Childrens Hosp Buffalo, Buffalo, NY 14260 USA
[3] Univ Rochester, Strong Mem Hosp, Rochester, NY 14642 USA
[4] Rady Childrens Hosp & Hlth Ctr, Albuquerque, NM USA
[5] Presbyterian Healthcare Serv, Albuquerque, NM USA
[6] Turku Univ Hosp, Dept Anaesthesiol Intens Care Emergency Care & Pa, FIN-20520 Turku, Finland
关键词
dexmedetomidine; pharmacokinetics; children; allometrics; DOSE DEXMEDETOMIDINE; CHILDREN; SEDATION; INFUSION; SIZE; PHARMACODYNAMICS; INFANTS; RAT; BUPIVACAINE; VOLUNTEERS;
D O I
10.1111/j.1460-9592.2009.03133.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
P>Background: Published dexmedetomidine pharmacokinetic studies in children are limited by participant numbers and restricted pathology. Pooling the available studies allows investigation of covariate effects. Methods: Data from four studies investigating dexmedetomidine pharmacokinetics after i.v. administration (n = 95) were combined to undertake a population pharmacokinetic analysis of dexmedetomidine time-concentration profiles (730 observations) using nonlinear mixed effects modeling (NONMEM). Estimates were standardized to a 70-kg adult using allometric size models. Results: Children had a mean age of 3.8 (median 3 years, range 1 week-14 years) and weight of 16.0 kg (median 13.3 kg, range 3.1-58.9 kg). Population parameter estimates (between subject variability) for a two-compartment model were clearance (CL) 42.1 (CV 30.9%) l center dot h-1 center dot 70 kg-1, central volume of distribution (V1) 56.3 (61.3%) l center dot 70 kg-1, inter-compartment clearance (Q) 78.3 (37.0%) l center dot h-1 center dot 70 kg-1 and peripheral volume of distribution (V2) 69.0 (47.0%) l center dot 70 kg-1. Clearance maturation with age was described using the Hill equation. Clearance increases from 18.2 l center dot h-1 center dot 70 kg-1 at birth in a term neonate to reach 84.5% of the mature value by 1 year of age. Children given infusion after cardiac surgery had 27% reduced clearance compared to a population given bolus dose. Simulation of published infusion rates that provide adequate sedation for intensive care patients found a target therapeutic concentration of between 0.4 and 0.8 mu g center dot l-1. Conclusions: The sedation target concentration is similar to that described for adults. Immature clearance in the first year of life and a higher clearance (when expressed as l center dot h-1 center dot kg-1) in small children dictate infusion rates that change with age. Extrapolation of dose from children given infusion in intensive care after cardiac surgery may not be applicable to those sedated for noninvasive procedures out of intensive care.
引用
收藏
页码:1119 / 1129
页数:11
相关论文
共 50 条
  • [21] The use of dexmedetomidine in intensive care sedation
    Antonelli, Massimo
    Conti, Giorgio
    Belisari, Andrea
    D'Angiolella, Lucia S.
    Mantovani, LorenzoG.
    Montella, Sabato
    Piacentini, Patrizio
    Ranieri, Marco
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2013, 14 : 3 - 28
  • [22] The use of dexmedetomidine in paediatric intensive care
    Piotrowski, Andrzej
    Gach, Marcin
    Wiszniewski, Dawid
    ANAESTHESIOLOGY INTENSIVE THERAPY, 2015, 47 (03) : 263 - +
  • [23] Sedation with dexmedetomidine in the intensive care setting
    Gerlach, Anthony T.
    Murphy, Claire V.
    OPEN ACCESS EMERGENCY MEDICINE, 2011, 3 : 77 - 85
  • [24] Dexmedetomidine for prevention of opioid/benzodiazepine withdrawal syndrome in pediatric intensive care unit: Interim analysis of a randomized controlled trial
    Mondardini, Maria Cristina
    Daverio, Marco
    Caramelli, Fabio
    Conti, Giorgio
    Zaggia, Cristina
    Lazzarini, Rossella
    Muscheri, Lidia
    Azzolina, Danila
    Gregori, Dario
    Sperotto, Francesca
    Amigoni, Angela
    PHARMACOTHERAPY, 2022, 42 (02): : 145 - 153
  • [25] BAYESIAN FORECASTING OF GENTAMICIN PHARMACOKINETICS IN PEDIATRIC INTENSIVE-CARE UNIT PATIENTS
    KRAUS, DM
    DUSIK, CM
    RODVOLD, KA
    CAMPBELL, MM
    KECSKES, SA
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1993, 12 (09) : 713 - 718
  • [26] Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine
    Gijsen, Matthias
    Vlasselaers, Dirk
    Spriet, Isabel
    Allegaert, Karel
    ANTIBIOTICS-BASEL, 2021, 10 (10):
  • [27] Cefepime population pharmacokinetics and dosing regimens optimization in pediatric intensive care unit
    De Cacqueray, N.
    Oualha, M.
    Hirt, D.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 158 - 158
  • [28] Cardiovascular Effects of Continuous Dexmedetomidine Infusion Without a Loading Dose in the Pediatric Intensive Care Unit
    Cummings, Brian M.
    Cowl, Allison S.
    Yager, Phoebe H.
    El Saleeby, Chadi M.
    Shank, Erik S.
    Noviski, Natan
    JOURNAL OF INTENSIVE CARE MEDICINE, 2015, 30 (08) : 512 - 517
  • [29] THE USE OF DEXMEDETOMIDINE IN PEDIATRIC INTENSIVE CARE UNIT PATIENTS REQUIRING NON-INVASIVE VENTILATION
    Morris, Susan
    Petrillo, Toni
    Fortenberry, James D.
    CRITICAL CARE MEDICINE, 2008, 36 (12) : A181 - A181
  • [30] Dexmedetomidine: Applications in pediatric critical care and pediatric anesthesiology
    Tobias, Joseph D.
    PEDIATRIC CRITICAL CARE MEDICINE, 2007, 8 (02) : 115 - 131